Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Baselga on Biomarker Research for Breast Cancer

September 16th 2017

José Baselga, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses biomarker research for patients with breast cancer.

Dr. Anderson on the Unmet Need in Low- and Middle-Income Breast Cancer Care

September 16th 2017

Benjamin O. Anderson, MD, a surgical oncologist at the Seattle Cancer Care Alliance, discusses the biggest unmet need for patients with breast cancer in low- and middle-income countries.

Multigene Testing Adds Complexity to Decision Making Process

September 16th 2017

Multigene panel testing offers a new but often puzzling tool for breast cancer treatment, since the results are often difficult to interpret, both for relative risk and risk management.

IBM's Watson has Potential Partnership With Oncologists

September 16th 2017

Even with advancements in technology, the prospect of artificial intelligence treating patients with cancer still remains out of reach. At least, for now.

"Opioid Epidemic" Increases Challenge of Treating Cancer Pain

September 15th 2017

Extra vigilance, careful management, and an emphasis on empathy makes treating cancer pain more effective during an opioid addiction epidemic.

Dr. Symmans on the Staging System for Breast Cancer

September 15th 2017

William F. Symmans, MD, professor of Pathology, The University of Texas MD Anderson Cancer Center, discusses the staging system for patients with breast cancer.

Paice on Current Pain Management for Breast Cancer

September 15th 2017

Judith Paice, PhD, RN, director of the Cancer Pain Program, Division of Hematology-Oncology, and research professor of Medicine, Northwestern University, discusses the pain management for patients with breast cancer.

Abemaciclib Improves PFS for HR+/HER2- Advanced Breast Cancer

September 10th 2017

The addition of abemaciclib to anastrozole or letrozole reduced the risk of progression or death by 46% compared with the non-steroidal aromatase inhibitors alone for previously untreated patients with HER2-negative, HR-positive advanced breast cancer.

Immune System Priming Prior to Checkpoint Blockade Improves Response in Metastatic TNBC

September 9th 2017

Turning a nonimmunogenic (“cold”) tumor into an immunogenic (“hot”) tumor appears feasible in patients with metastatic triple negative breast cancer, thereby improving sensitivity to immune therapy with nivolumab.

Dr. Esteva on Next-Generation Sequencing in Metastatic Breast Cancer

September 8th 2017

Francisco J. Esteva, MD, PhD, medical oncologist, NYU Langone Medical Center, discusses next-generation sequencing in metastatic breast cancer.

Taselisib, Letrozole Combination Active for ER+, HER2- Early Breast Cancer

September 8th 2017

Taselisib added to standard letrozole (Femara) improved the objective response rate compared to letrozole with a placebo in postmenopausal women with estrogen receptor-positive and HER2-negative early breast cancer.

Dr. Tolaney Discusses Pertuzumab in HER2+ Breast Cancer

September 8th 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Dr. Tolaney on the Current Treatment Landscape for HER2+ Breast Cancer

September 7th 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Z-endoxifen Shows Promise in Endocrine Refractory Breast Cancer

September 5th 2017

Z-endoxifen, a potent derivative of the drug tamoxifen, induced tumor shrinkage in women with ER-positive metastatic breast cancer who had progressed on standard anti-estrogen therapies.

Finding the Right Place for Dual HER2 Blockade in Breast Cancer and Beyond

September 4th 2017

Although drugs that target HER2 have transformed the prognosis for many patients with breast cancer, the development of resistant disease remains a significant clinical challenge.

Expert Discusses State of Immunotherapy in Breast Cancer Subtypes

September 1st 2017

Sylvia Adams, MD, discusses ongoing clinical developments with immunotherapy in breast cancer.

Dr. Pegram on Challenges Facing the Treatment of HER2-Positive Breast Cancer

September 1st 2017

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses challenges facing the treatment of patients with HER2-positive breast cancer.

Dr. Holmes on Neoadjuvant Endocrine Therapy in Breast Cancer

September 1st 2017

Frankie Ann Holmes, MD, a physician at Texas Oncology, discusses neoadjuvant endocrine therapy for patients with breast cancer.

Mamounas Sheds Light on Adjuvant Endocrine Therapy in Breast Cancer

September 1st 2017

Eleftherios (Terry) P. Mamounas, MD, discusses whether 10 years was superior to the widely practiced 5 years of adjuvant hormone therapy for patients with breast cancer.

Dr. Mamounas on Adjuvant Endocrine Therapy for Breast Cancer

September 1st 2017

Eleftherios (Terry) P. Mamounas, MD, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses adjuvant endocrine therapy for patients with breast cancer.